Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Apatinib
2. Rivoceranib
3. Rivoceranib Mesylate
4. Yn-968d1
5. Yn968d1
1. 1218779-75-9
2. Rivoceranib Mesylate
3. Yn968d1
4. Yn-968d1
5. Yn 968d1
6. Tk02x14asj
7. Rivoceranib Mesylate (usan)
8. 3-pyridinecarboxamide, N-(4-(1-cyanocyclopentyl)phenyl)-2-((4-pyridinylmethyl)amino)-, Methanesulfonate (1:1)
9. Rivoceranib Mesylate [usan]
10. N-(4-(1-cyanocyclopentyl)phenyl)-2-((pyridin-4-ylmethyl)amino)nicotinamide Mesylate
11. N-[4-(1-cyanocyclopentyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide;methanesulfonic Acid
12. Unii-tk02x14asj
13. Apatinib?mesylate
14. 3-pyridinecarboxamide, N-[4-(1-cyanocyclopentyl)phenyl]-2-[(4-pyridinylmethyl)amino]-, Methanesulfonate (1:1)
15. Alitan (tn)
16. Apatinib-yn968d1
17. Apatinib - Yn968d1
18. Mls006011286
19. Chembl3545414
20. Schembl21847695
21. Dtxsid80153427
22. Hms3655h12
23. Bcp15234
24. Apatinib (registered Name In China)
25. Bdbm50152828
26. S2221
27. Rivoceranib Mesylate [who-dd]
28. Akos026750547
29. Bcp9000308
30. Ccg-269641
31. Cs-0694
32. Sb16589
33. N-(4-(1-cyanocyclopentyl)phenyl)-2-((pyridin-4-ylmethyl)amino)nicotinamide Methanesulfonate
34. Ac-35390
35. Hy-13342
36. Smr004703036
37. Sw220296-1
38. D11289
39. N-(4-(1-cyanocyclopentyl)phenyl)-2-(pyridin-4-ylmethylamino)nicotinamide Mesylate
40. N-(4-(1-cyanocyclopentyl)phenyl)-2-((pyridin-4-ylmethyl)amino)pyridine-3-carboxamide Mesylate
41. N-(4-(1-cyanocyclopentyl)phenyl)-2-((pyridin-4-ylmethyl)amino)pyridine-3-carboxamide Monomethanesulfonate Salt
| Molecular Weight | 493.6 g/mol |
|---|---|
| Molecular Formula | C25H27N5O4S |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 6 |
| Exact Mass | 493.17837553 g/mol |
| Monoisotopic Mass | 493.17837553 g/mol |
| Topological Polar Surface Area | 153 Ų |
| Heavy Atom Count | 35 |
| Formal Charge | 0 |
| Complexity | 701 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
Antineoplastic Agents
Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)
Protein Kinase Inhibitors
Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)
ABOUT THIS PAGE
59
PharmaCompass offers a list of apatinib mesylate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right apatinib mesylate manufacturer or apatinib mesylate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred apatinib mesylate manufacturer or apatinib mesylate supplier.
PharmaCompass also assists you with knowing the apatinib mesylate API Price utilized in the formulation of products. apatinib mesylate API Price is not always fixed or binding as the apatinib mesylate Price is obtained through a variety of data sources. The apatinib mesylate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A apatinib mesylate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of apatinib mesylate, including repackagers and relabelers. The FDA regulates apatinib mesylate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. apatinib mesylate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A apatinib mesylate supplier is an individual or a company that provides apatinib mesylate active pharmaceutical ingredient (API) or apatinib mesylate finished formulations upon request. The apatinib mesylate suppliers may include apatinib mesylate API manufacturers, exporters, distributors and traders.
apatinib mesylate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of apatinib mesylate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right apatinib mesylate GMP manufacturer or apatinib mesylate GMP API supplier for your needs.
A apatinib mesylate CoA (Certificate of Analysis) is a formal document that attests to apatinib mesylate's compliance with apatinib mesylate specifications and serves as a tool for batch-level quality control.
apatinib mesylate CoA mostly includes findings from lab analyses of a specific batch. For each apatinib mesylate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
apatinib mesylate may be tested according to a variety of international standards, such as European Pharmacopoeia (apatinib mesylate EP), apatinib mesylate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (apatinib mesylate USP).
